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To the Editor,
Acute hepatitis A virus (AHAV) infection is a self-limited 
condition that usually spontaneously recovers in 
2–8 weeks. While in children under 6 years of age AHAV 
is often asymptomatic, >70% of adults manifest symp-
toms together with typical laboratory findings [1]. AHAV 
is serologically diagnosed by the detection of anti-HAV 
IgM, which persists 2–6  months after infection. Labora-
tory results during AHAV show a marked increase (usually 
10 to 40 times the upper reference limit [URL]) in serum 
alanine aminotransferase (ALT) activity, together with 
high total bilirubin (TB) (average peak of 171.0 μmol/L, 
mainly consisting of the conjugated form) and moder-
ately (<3 URL) increased alkaline phosphatase (ALP) 
and γ-glutamyltransferase (GGT) [2]. With resolution of 
AHAV, conjugated bilirubin (CB) is rapidly cleared and its 
serum concentrations return to normal quickly. However, 
10%–20% of patients develop prolonged cholestasis 
lasting for >6 months [1].
Bilirubin, which is a major end-product of heme 
breakdown, is physiologically glucuronidated in the liver 
and then excreted into the bile. The mechanisms of bili-
rubin excretion, and of hyperbilirubinemia causes, are 
largely understood. Unconjugated bilirubin (UB) enters 
the hepatocyte by passive transmembrane diffusion com-
bined with active mediated transport. In the hepatocyte, 
UB is bound to ligandin and transported to the endoplas-
mic reticulum, where it is conjugated into bilirubin glu-
curonide by UDP glucuronosyltransferase (UGT) 1A1, and 
excreted into the bile by ATP-binding cassette (ABC) trans-
porters ABCC2 and, to a lesser extent, by ABCG2. Under 
pathophysiological conditions, such as acute hepatitis 
or cholestasis, the CB back into blood by the basolateral 
ABCC3 transporter and then the solute carrier organic 
anion (SLCO) transporters 1B1 and 1B3 mediate its hepatic 
reuptake [3]. Several inherited disorders characterized 
by impaired bilirubin conjugation or transport result in 
various degrees of unconjugated or conjugated hyperbili-
rubinemia, respectively [4].
Here, we report a case of prolonged severe hyperbili-
rubinemia in a patient with pre-existing AHAV, in which 
we were however, unable to show an evident persistence 
of cholestasis. A 33-year-old man was admitted at the 
Emergency Department of our hospital on April 7, 2017, 
6  weeks after an AHAV diagnosis performed in another 
hospital. The patient, strongly jaundiced, presented asthe-
nia, nausea, diarrhea, pruritus and hyperchromic urine. 
Blood tests revealed a moderate increase of serum ALT 
activity (202 U/L; URL: 59 U/L), in line with the expected 
AHAV resolution, but an unexpectedly markedly elevated 
serum TB (625.9 μmol/L, with CB of 480.5 μmol/L; TB URL: 
20.5 μmol/L, CB URL: 5.1 μmol/L). The presence of anti-
HAV IgM (slightly positive) and anti-HAV IgG confirmed 
the previous AHAV diagnosis. Other concomitant condi-
tions (such as hepatitis B and C infection, syphilis, auto-
immune disease and drug toxicity) were excluded. Steroid 
therapy was immediately started, but without any clini-
cal improvement or significant decrease in serum TB/CB 
concentrations (Figure 1). A magnetic resonance cholan-
giopancreatography (MRCP) was therefore carried out, 
revealing no signs of intra- or extra-hepatic cholestasis, 
besides those already suggested by the steadily normal 
values of GGT and the only slight (≤2 times the URL) 
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elevation of ALP in the serum (Figure 1). In the following 
weeks, bilirubin in the serum started to slowly decrease, 
reaching 157.3 μmol/L for TB and 114.6 μmol/L for CB, 
respectively, the day of hospital discharge (May 29, 2017). 
Seven days later (15 weeks after the AHAV onset), a further 
laboratory evaluation showed a TB concentration of 95.8 
μmol/L and a CB concentration of 66.7 μmol/L, indicating 
their normalization trend (Figure 1).
To explore the possible contribution of genetics on 
the anomalous persistence of marked hyperbilirubine-
mia, we conducted a genetic analysis. The patient signed 
a written informed consent before genotyping. We inves-
tigated the major functional variants that map into the 
genes involved in the glucuronidation and in the cycle 
of bilirubin efflux and bilirubin re-uptake. Genomic DNA 
was isolated from the peripheral blood cells using an 
automatic DNA extraction system (Maxwell 16 System, 
Promega), according to the manufacturer’s instructions. 
All genotypes were determined by real-time PCR, using 
a panel of LightSNiP from TIB-MolBiol on LightCycler 
480 (Roche Diagnostics). First, we investigated the pres-
ence of the UGT1A1*28 (rs8175347) allele, which contains 
an extra-TA repeat in the TATA box promoter region: 
7 (TA) in *28 allele, compared to six (TA) repeats in the 
common *1 allele. This extra-TA repeat decreases the rate 
of transcription of the UGT1A1 gene and thus decreases 
the enzyme activity and the glucuronidation of biliru-
bin [5]. Regarding the efflux transporters, we checked 
the presence of the functional single nucleotide poly-
morphisms (SNP) in the ABCC2 (–24C>T/rs717620) and 
ABCG2 (c.421C>A/rs2231142) genes, which have been 
found to influence transport activity in several studies 
[6, 7]. Finally, as SLCO1B1 is predominantly expressed 
at the basolateral membrane of hepatocytes, we inves-
tigated the presence of the 521T>C variant, located in 
exon 5 of the gene (rs4149056), resulting in decreased 
uptake transport activity [8]. The genetic test of the patient 
revealed the presence of UGT1A1*28 in the homozygous 
state and ABCC2 –24C>T, ABCG2 c.421C>A and SLCO1B1 
521T>C in the heterozygous state (Figure 2A). The simulta-
neous presence of all the defective alleles may explain the 
occurrence of the extremely high levels of bilirubin and of 
their unexpectedly prolonged persistence observed in our 
patient. We hypothesize that the impaired apical mem-
brane efflux may cause an activation of compensatory 
pathway for CB efflux into sinusoidal blood across the 
basolateral membrane, but, due to the presence of SNP in 
the SLCO1B1, the hepatic reuptake may be reduced (Figure 
2B). Moreover, functional SNP mapping into the SLCO1B1 
gene may also contribute to the reduction of the active 
transport of UB in the hepatocyte and therefore influence 
serum bilirubin concentrations in association with the 
well-known effect of the UGT1A1*28 allele (Figure 2B).
Krawczyk et  al. previously described a possible 
association between two polymorphisms in the hepato-
canalicular bile salt transporter ABCB11 and phospho-
lipids transporter ABCB4 and severe liver cholestasis 
following AHAV [9]. In our patient, due to the absence 
of cholestasis as suggested by unchanged or slightly 
modified serum concentrations of enzymatic markers 
of cholestasis (ALP and GGT) and confirmed by MRCP, 
we speculated for the first time that the severe and 
prolonged mixed hyperbilirubinemia may derive from 
a genetic predisposition causing a metabolic deficit. A 
dual hereditary jaundice, due to a compound defect of 
bilirubin conjugation (Gilbert syndrome/UGT1A1) and 
transport (Dubin-Johnson syndrome/ABCC2) was previ-
ously described [10]; however, our case presented two 
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Figure 1: Trend of laboratory tests in the studied patient.
(A) Serum liver enzymes: alanine aminotransferase (blue line), 
alkaline phosphatase (green line) and γ-glutamyltransferase (red 
line). (B) Total bilirubin (green line), conjugated bilirubin (blue line) 
and unconjugated bilirubin (red line) in serum, respectively.  
URL, upper reference limit.
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other additional hereditary defects in the SLCO1B1 and 
ABCG2 genes.
In conclusion, in our opinion the concomitant detec-
tion of defective variants of genes involved in the bilirubin 
pathway was able to explain the hampered resolution of 
the hyperbilirubinemia in our patient with pre-existing 
AHAV. Although other genetic variants or other genes 
involved in the hepatic cycle of bilirubin can add to our 
findings, our observation highlights the importance of the 
molecular mechanisms underlying a hyperbilirubinemia 
condition. Further investigations are needed to define the 
proportion of patients with this specific genetic profile, 
who may show prolonged severe hyperbilirubinemia after 
AHAV infection.
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Figure 2: Bilirubin metabolism in studied patient.
(A) Results of performed genetic analyses. (B) Liver bilirubin pathway, with genetic defects detected in the studied hyperbilirubinemic 
patient. Unconjugated bilirubin is passively and actively absorbed into the liver. Defective SLCO1B1 may reduce the active transport of 
unconjugated bilirubin into hepatocytes. In the hepatocytes, bilirubin is conjugated to form bilirubin glucuronide by UGT1A1 and then 
excreted into the bile by ABCC2 and ABCG2. Due to the decreased activity of ABCC2 and ABCG2, conjugated bilirubin back into the blood. 
Here, the defective activity of SLCO1B1 cannot mediate its hepatic reuptake. Red crosses indicate defective gene activity. MAF, minor allele 
frequency (www.ensembl.org).
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